XNASCOCP
Market cap20mUSD
Jan 17, Last price
1.98USD
1D
-1.74%
1Q
-4.67%
Jan 2017
-57.25%
IPO
-96.43%
Name
Cocrystal Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-66.63%
Rev. gr., 5y
90.56%
Revenues
0k
Net income
-18m
L-53.70%
CFO
-15m
L-31.58%
Earnings
Mar 26, 2025
Profile
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 36,328 | 18,379 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (36,328) | (18,379) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 8 | ||||||||
Tax Rate | |||||||||
NOPAT | (36,328) | (18,387) | |||||||
Net income | (17,984) -53.70% | (38,845) 173.77% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,000 | ||||||||
BB yield | -24,066.01% | ||||||||
| Debt | |||||||||
Debt current | 480 | 240 | |||||||
Long-term debt | 3,466 | 354 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (22,407) | (36,550) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (14,666) | (21,435) | |||||||
CAPEX | (118) | (74) | |||||||
Cash from investing activities | (118) | (74) | |||||||
Cash from financing activities | 3,993 | (27) | |||||||
FCF | (35,776) | (20,130) | |||||||
| Balance | |||||||||
Cash | 26,353 | 37,144 | |||||||
Long term investments | |||||||||
Excess cash | 26,353 | 37,144 | |||||||
Stockholders' equity | (315,904) | (297,922) | |||||||
Invested Capital | 344,381 | 337,786 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 10 | 8,143 | |||||||
Price | 1.72 -11.68% | 1.95 -75.00% | |||||||
Market cap | 17 -99.90% | 15,879 -97.70% | |||||||
EV | (22,390) | (20,671) | |||||||
EBITDA | (37,716) | (17,991) | |||||||
EV/EBITDA | 0.59 | 1.15 | |||||||
Interest | 2 | ||||||||
Interest/NOPBT | |||||||||